Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 13 Issue 4, April 2017

Fatty acid synthase (FAS) is a multidomain enzyme complex that can be engineered to generate non-native fatty acids and ketones. The cover depicts the structure of yeast FAS in cross-section, with a miniature factory inside its reaction chamber to represent the production and export of these molecules. Cover design by Erin Dewalt, from imagery provided by Zhiwei Zhu and Martin Grininger. Brief Communications, p360 and p363; News and Views, p344

Commentary

  • Nuclear magnetic resonance spectroscopy is transforming our views of proteins by revealing how their structures and dynamics are closely intertwined to underlie their functions and interactions. Compelling representations of proteins as statistical ensembles are uncovering the presence and biological relevance of conformationally heterogeneous states, thus gradually making it possible to go beyond the dichotomy between order and disorder through more quantitative descriptions that span the continuum between them.

    • Pietro Sormanni
    • Damiano Piovesan
    • Michele Vendruscolo
    Commentary

    Advertisement

Top of page ⤴

Research Highlights

Top of page ⤴

News & Views

  • Systematically modifying biological assembly lines for the synthesis of novel products remains a challenge. Structural insights and computational modeling have now paved the way for efficient redesigns of giant fatty acid synthases.

    • Timm Maier
    News & Views
  • New small-molecule inhibitors of the histone methyltransferase PRC2 interfere with the allosteric activation of enzymatic activity. These compounds are effective against PRC2-dependent tumors that are resistant to catalytic inhibitors and provide important new tools for altering chromatin regulation.

    • Daniel Holoch
    • Raphaël Margueron
    News & Views
  • Pharmacological chaperones are small drugs that stabilize a protein's fold and are being developed to treat diseases arising from protein misfolding. A mathematical framework to model their activity in cells enables insight into their mechanism and capacity to rescue protein foldedness.

    • Danny M Hatters
    News & Views
  • In early-stage developing neurons, the cAMP–PKA (protein kinase A) signaling pathway is strongly inhibited. This negative control is later removed, unleashing cAMP–PKA signaling, particularly in distal axonal parts, thus allowing for axonal growth.

    • Pierre Vincent
    • Liliana R Castro
    News & Views
Top of page ⤴

Review Article

  • A review of the roles of cyclic dinucleotides (CDNs) in signaling systems including transcription, ion transport, bacterial secretion and eukaryotic immune responses, highlighting the diverse binding modes of CDNs by target proteins and functional insights gained from structural studies.

    • Petya Violinova Krasteva
    • Holger Sondermann
    Review Article
Top of page ⤴

Brief Communication

  • Integration of heterologous enzymes into the reaction chambers of fungal fatty acid synthases (FASs) demonstrates the capacity of these megaenzymes for engineered production of short- and medium-chain fatty acids and methyl ketones.

    • Zhiwei Zhu
    • Yongjin J Zhou
    • Jens Nielsen
    Brief Communication
  • Pharmacological chaperones improve folding of destabilized Escherichia coli dihydrofolate reductase (DHFR) and human disease-linked α-galactosidase A (α-GAL) by biasing the kinetic partitioning between folding, aggregation, and degradation. Chaperoning spares DHFR from aggregation and α-GAL from degradation.

    • Karan S Hingorani
    • Matthew C Metcalf
    • Lila M Gierasch
    Brief Communication
Top of page ⤴

Article

Top of page ⤴

Search

Quick links